JP5767631B2 - バニロイド受容体リガンドとしての置換された芳香族カルボキサミドおよび尿素誘導体 - Google Patents
バニロイド受容体リガンドとしての置換された芳香族カルボキサミドおよび尿素誘導体 Download PDFInfo
- Publication number
- JP5767631B2 JP5767631B2 JP2012508950A JP2012508950A JP5767631B2 JP 5767631 B2 JP5767631 B2 JP 5767631B2 JP 2012508950 A JP2012508950 A JP 2012508950A JP 2012508950 A JP2012508950 A JP 2012508950A JP 5767631 B2 JP5767631 B2 JP 5767631B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- pyrazol
- trifluoromethyl
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 aromatic carboxamide Chemical class 0.000 title claims description 113
- 108010062740 TRPV Cation Channels Proteins 0.000 title description 15
- 102000011040 TRPV Cation Channels Human genes 0.000 title description 14
- 150000003672 ureas Chemical class 0.000 title description 4
- 239000003446 ligand Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 900
- 125000001424 substituent group Chemical group 0.000 claims description 217
- 229910052801 chlorine Inorganic materials 0.000 claims description 214
- 229910052794 bromium Inorganic materials 0.000 claims description 208
- 229910052731 fluorine Inorganic materials 0.000 claims description 206
- 229910052740 iodine Inorganic materials 0.000 claims description 199
- 150000001875 compounds Chemical class 0.000 claims description 192
- 229920006395 saturated elastomer Polymers 0.000 claims description 149
- 125000003118 aryl group Chemical group 0.000 claims description 117
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 117
- 229910052799 carbon Inorganic materials 0.000 claims description 114
- 125000001072 heteroaryl group Chemical group 0.000 claims description 114
- 125000000623 heterocyclic group Chemical class 0.000 claims description 90
- 229910052760 oxygen Inorganic materials 0.000 claims description 89
- 125000006376 (C3-C10) cycloalkyl group Chemical class 0.000 claims description 80
- 208000002193 Pain Diseases 0.000 claims description 78
- 229910052757 nitrogen Inorganic materials 0.000 claims description 78
- 229910052717 sulfur Inorganic materials 0.000 claims description 65
- 238000006243 chemical reaction Methods 0.000 claims description 63
- 229910004013 NO 2 Inorganic materials 0.000 claims description 61
- 208000011117 substance-related disease Diseases 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 57
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 54
- 230000036961 partial effect Effects 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 125000004076 pyridyl group Chemical group 0.000 claims description 45
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 44
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 43
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 40
- 125000004432 carbon atom Chemical group C* 0.000 claims description 39
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 39
- 206010013663 drug dependence Diseases 0.000 claims description 38
- 230000036407 pain Effects 0.000 claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 31
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 31
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 29
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 208000007848 Alcoholism Diseases 0.000 claims description 28
- 229960002504 capsaicin Drugs 0.000 claims description 27
- 235000017663 capsaicin Nutrition 0.000 claims description 27
- 108010025083 TRPV1 receptor Proteins 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 22
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 22
- 206010013654 Drug abuse Diseases 0.000 claims description 21
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 claims description 21
- 239000002671 adjuvant Substances 0.000 claims description 21
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 21
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 21
- 125000001544 thienyl group Chemical group 0.000 claims description 21
- 206010061218 Inflammation Diseases 0.000 claims description 20
- 230000004054 inflammatory process Effects 0.000 claims description 20
- 208000004296 neuralgia Diseases 0.000 claims description 19
- 208000021722 neuropathic pain Diseases 0.000 claims description 19
- 208000000094 Chronic Pain Diseases 0.000 claims description 18
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 18
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 18
- 108050004388 Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 claims description 18
- 208000020629 overactive bladder Diseases 0.000 claims description 18
- 238000006467 substitution reaction Methods 0.000 claims description 18
- 208000004454 Hyperalgesia Diseases 0.000 claims description 16
- 208000005298 acute pain Diseases 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 230000004770 neurodegeneration Effects 0.000 claims description 16
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 16
- 229910052720 vanadium Inorganic materials 0.000 claims description 16
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 15
- 206010046543 Urinary incontinence Diseases 0.000 claims description 15
- 239000000556 agonist Substances 0.000 claims description 15
- 125000003107 substituted aryl group Chemical group 0.000 claims description 15
- 208000009935 visceral pain Diseases 0.000 claims description 15
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 14
- 208000030814 Eating disease Diseases 0.000 claims description 13
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 13
- 201000007930 alcohol dependence Diseases 0.000 claims description 13
- 235000014632 disordered eating Nutrition 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 208000027418 Wounds and injury Diseases 0.000 claims description 12
- 208000010877 cognitive disease Diseases 0.000 claims description 12
- 208000023504 respiratory system disease Diseases 0.000 claims description 12
- 210000003491 skin Anatomy 0.000 claims description 12
- 208000028698 Cognitive impairment Diseases 0.000 claims description 11
- 208000019695 Migraine disease Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 206010027599 migraine Diseases 0.000 claims description 11
- 125000002757 morpholinyl group Chemical group 0.000 claims description 11
- 210000003932 urinary bladder Anatomy 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 208000006820 Arthralgia Diseases 0.000 claims description 10
- 208000023105 Huntington disease Diseases 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 210000001508 eye Anatomy 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 208000017520 skin disease Diseases 0.000 claims description 10
- 206010001584 alcohol abuse Diseases 0.000 claims description 9
- 208000025746 alcohol use disease Diseases 0.000 claims description 9
- 238000011161 development Methods 0.000 claims description 9
- 210000000936 intestine Anatomy 0.000 claims description 9
- 206010027175 memory impairment Diseases 0.000 claims description 9
- 210000002850 nasal mucosa Anatomy 0.000 claims description 9
- 125000003386 piperidinyl group Chemical group 0.000 claims description 9
- 208000035154 Hyperesthesia Diseases 0.000 claims description 8
- 208000004880 Polyuria Diseases 0.000 claims description 8
- 206010053552 allodynia Diseases 0.000 claims description 8
- 230000007278 cognition impairment Effects 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 230000035619 diuresis Effects 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 210000005036 nerve Anatomy 0.000 claims description 8
- 229940005483 opioid analgesics Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000012429 reaction media Substances 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 206010011224 Cough Diseases 0.000 claims description 7
- 206010012735 Diarrhoea Diseases 0.000 claims description 7
- 208000003251 Pruritus Diseases 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 7
- 208000022531 anorexia Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 206010061428 decreased appetite Diseases 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- RLWGDRLXZSLGHV-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[(4-tert-butylphenyl)methyl]urea Chemical compound C1=C(OCCN)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(C)(C)C)=C1 RLWGDRLXZSLGHV-UHFFFAOYSA-N 0.000 claims description 6
- 206010006895 Cachexia Diseases 0.000 claims description 6
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 claims description 6
- 206010015946 Eye irritation Diseases 0.000 claims description 6
- 208000009889 Herpes Simplex Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000025747 Rheumatic disease Diseases 0.000 claims description 6
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 6
- 206010047642 Vitiligo Diseases 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 210000000748 cardiovascular system Anatomy 0.000 claims description 6
- 239000007822 coupling agent Substances 0.000 claims description 6
- 208000000718 duodenal ulcer Diseases 0.000 claims description 6
- 231100000013 eye irritation Toxicity 0.000 claims description 6
- 201000005917 gastric ulcer Diseases 0.000 claims description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 6
- 238000002690 local anesthesia Methods 0.000 claims description 6
- 230000037023 motor activity Effects 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 claims description 6
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 claims description 6
- 229940073454 resiniferatoxin Drugs 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 208000032841 Bulimia Diseases 0.000 claims description 5
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 5
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
- 206010052428 Wound Diseases 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000000532 dioxanyl group Chemical group 0.000 claims description 5
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000002971 oxazolyl group Chemical group 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 230000001568 sexual effect Effects 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000001425 triazolyl group Chemical group 0.000 claims description 5
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 4
- 230000001054 cortical effect Effects 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 230000007794 irritation Effects 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 4
- 230000036262 stenosis Effects 0.000 claims description 4
- 208000037804 stenosis Diseases 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000037007 arousal Effects 0.000 claims description 3
- 230000003376 axonal effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 208000021760 high fever Diseases 0.000 claims description 3
- 229940080818 propionamide Drugs 0.000 claims description 3
- ZUVAHVBRASSMQZ-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-3-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3OCOC3=CC=2)N1C1=CC=CC(Cl)=C1 ZUVAHVBRASSMQZ-UHFFFAOYSA-N 0.000 claims description 2
- WYBOZFUMORGCRV-UHFFFAOYSA-N 1-(1,3-benzothiazol-5-yl)-3-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3N=CSC3=CC=2)N1C1=CC=CC(Cl)=C1 WYBOZFUMORGCRV-UHFFFAOYSA-N 0.000 claims description 2
- FCTLCIFCWATOJV-UHFFFAOYSA-N 1-(1,3-benzothiazol-6-yl)-3-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3SC=NC3=CC=2)N1C1=CC=CC(Cl)=C1 FCTLCIFCWATOJV-UHFFFAOYSA-N 0.000 claims description 2
- BEGBNKHCEJEPHR-UHFFFAOYSA-N 1-(1,3-benzoxazol-5-yl)-3-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3N=COC3=CC=2)N1C1=CC=CC(Cl)=C1 BEGBNKHCEJEPHR-UHFFFAOYSA-N 0.000 claims description 2
- OWYFAENZVWAAGQ-UHFFFAOYSA-N 1-(1,3-benzoxazol-6-yl)-3-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3OC=NC3=CC=2)N1C1=CC=CC(Cl)=C1 OWYFAENZVWAAGQ-UHFFFAOYSA-N 0.000 claims description 2
- ZYJMFWDGJQRBQF-UHFFFAOYSA-N 1-(1-chloroisoquinolin-5-yl)-3-[[2-piperidin-1-yl-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C3=CC=NC(Cl)=C3C=CC=2)N1N1CCCCC1 ZYJMFWDGJQRBQF-UHFFFAOYSA-N 0.000 claims description 2
- BWPOCUHLLGFHQH-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[2-(thiophen-2-ylmethoxy)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=3C=NNC=3C=CC=2)N1OCC1=CC=CS1 BWPOCUHLLGFHQH-UHFFFAOYSA-N 0.000 claims description 2
- BBTCXSCQIOBJCO-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[2-[(4-methoxyphenyl)methyl]-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound C1=CC(OC)=CC=C1CN1C(CNC(=O)NC=2C=3C=NNC=3C=CC=2)=CC(C(F)(F)F)=N1 BBTCXSCQIOBJCO-UHFFFAOYSA-N 0.000 claims description 2
- PKIMHQNALGNIIQ-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-5-yl)-3-[[2-(3,4-dimethylphenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound C1=C(C)C(C)=CC=C1N1C(CNC(=O)NC=2C=C3CCCC3=CC=2)=CC(C(F)(F)F)=N1 PKIMHQNALGNIIQ-UHFFFAOYSA-N 0.000 claims description 2
- ZYFIDFCKLPKOFW-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-5-yl)-3-[[2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound C1=CC(F)=CC=C1N1C(CNC(=O)NC=2C=C3CCCC3=CC=2)=CC(C(F)(F)F)=N1 ZYFIDFCKLPKOFW-UHFFFAOYSA-N 0.000 claims description 2
- UKKAXTOEMUJJPG-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-5-yl)-3-[[2-(4-methoxyphenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound C1=CC(OC)=CC=C1N1C(CNC(=O)NC=2C=C3CCCC3=CC=2)=CC(C(F)(F)F)=N1 UKKAXTOEMUJJPG-UHFFFAOYSA-N 0.000 claims description 2
- VNVUAKJVLPMKKU-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-5-yl)-3-[[2-(dipropylamino)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound CCCN(CCC)N1N=C(C(F)(F)F)C=C1CNC(=O)NC1=CC=C(CCC2)C2=C1 VNVUAKJVLPMKKU-UHFFFAOYSA-N 0.000 claims description 2
- JTIAVGBCYJPCHT-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-5-yl)-3-[[2-[4-(trifluoromethoxy)phenyl]-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound C1=CC(OC(F)(F)F)=CC=C1N1C(CNC(=O)NC=2C=C3CCCC3=CC=2)=CC(C(F)(F)F)=N1 JTIAVGBCYJPCHT-UHFFFAOYSA-N 0.000 claims description 2
- OAHCPDZXYXNRSR-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-5-yl)-3-[[5-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3CCCC3=CC=2)N1C1=CC=C(C(F)(F)F)C=C1 OAHCPDZXYXNRSR-UHFFFAOYSA-N 0.000 claims description 2
- GUPBPLJNKPBBRQ-UHFFFAOYSA-N 1-(3-chloroisoquinolin-5-yl)-3-[[2-piperidin-1-yl-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C3=CC(Cl)=NC=C3C=CC=2)N1N1CCCCC1 GUPBPLJNKPBBRQ-UHFFFAOYSA-N 0.000 claims description 2
- ACQCQISWSOMQLM-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-3-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3N=CNC3=CC=2)N1C1=CC=CC(Cl)=C1 ACQCQISWSOMQLM-UHFFFAOYSA-N 0.000 claims description 2
- OTVDUMBPFDUTPU-UHFFFAOYSA-N 1-(5-chloro-1h-indazol-4-yl)-3-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=3C=NNC=3C=CC=2Cl)N1C1=CC=CC(Cl)=C1 OTVDUMBPFDUTPU-UHFFFAOYSA-N 0.000 claims description 2
- BMTYNMKBRYVZER-UHFFFAOYSA-N 1-(7-hydroxynaphthalen-1-yl)-3-[[2-piperidin-1-yl-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound C12=CC(O)=CC=C2C=CC=C1NC(=O)NCC1=CC(C(F)(F)F)=NN1N1CCCCC1 BMTYNMKBRYVZER-UHFFFAOYSA-N 0.000 claims description 2
- ATABGOFXBKZNIL-UHFFFAOYSA-N 1-[(5-tert-butyl-2-cyclohexylsulfanylpyrazol-3-yl)methyl]-3-(2-methylquinolin-5-yl)urea Chemical compound C=1C=CC2=NC(C)=CC=C2C=1NC(=O)NCC1=CC(C(C)(C)C)=NN1SC1CCCCC1 ATABGOFXBKZNIL-UHFFFAOYSA-N 0.000 claims description 2
- COOVGMXLFDILNP-UHFFFAOYSA-N 1-[(5-tert-butyl-2-pyridin-2-ylpyrazol-3-yl)methyl]-3-(6-fluoro-1h-indazol-4-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=3C=NNC=3C=C(F)C=2)N1C1=CC=CC=N1 COOVGMXLFDILNP-UHFFFAOYSA-N 0.000 claims description 2
- MTBOHROPUSRDDI-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-4-methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1h-indazol-4-yl)urea Chemical compound N1=C(C(F)(F)F)C(C)=C(CNC(=O)NC=2C=3C=NNC=3C=CC=2)N1C1=CC=CC(Cl)=C1 MTBOHROPUSRDDI-UHFFFAOYSA-N 0.000 claims description 2
- OPQBXYLHKFNWJH-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1-methylindazol-4-yl)urea Chemical compound C1=CC=C2N(C)N=CC2=C1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 OPQBXYLHKFNWJH-UHFFFAOYSA-N 0.000 claims description 2
- YJVCGMRRKRMMAM-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1-methylindol-4-yl)urea Chemical compound C1=CC=C2N(C)C=CC2=C1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 YJVCGMRRKRMMAM-UHFFFAOYSA-N 0.000 claims description 2
- IMADJLCKZYXRAK-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1-oxo-2h-isoquinolin-5-yl)urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C3=C(C(NC=C3)=O)C=CC=2)N1C1=CC=CC(Cl)=C1 IMADJLCKZYXRAK-UHFFFAOYSA-N 0.000 claims description 2
- NAHYRLOXRZTJAL-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1h-indazol-4-yl)urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=3C=NNC=3C=CC=2)N1C1=CC=CC(Cl)=C1 NAHYRLOXRZTJAL-UHFFFAOYSA-N 0.000 claims description 2
- XSLZAKJWMCUCSX-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1h-indazol-5-yl)urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3C=NNC3=CC=2)N1C1=CC=CC(Cl)=C1 XSLZAKJWMCUCSX-UHFFFAOYSA-N 0.000 claims description 2
- YKQFQLORSLOABC-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1h-indol-4-yl)urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=3C=CNC=3C=CC=2)N1C1=CC=CC(Cl)=C1 YKQFQLORSLOABC-UHFFFAOYSA-N 0.000 claims description 2
- MGIPRFBECFSHNE-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1h-indol-5-yl)urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3C=CNC3=CC=2)N1C1=CC=CC(Cl)=C1 MGIPRFBECFSHNE-UHFFFAOYSA-N 0.000 claims description 2
- VWCLOGLDZMLRLY-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(2,3-dihydro-1,4-benzodioxin-6-yl)urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3OCCOC3=CC=2)N1C1=CC=CC(Cl)=C1 VWCLOGLDZMLRLY-UHFFFAOYSA-N 0.000 claims description 2
- XQNYXRCXFSNCOW-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(2-hydroxy-2,3-dihydro-1h-inden-4-yl)urea Chemical compound C=12CC(O)CC2=CC=CC=1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 XQNYXRCXFSNCOW-UHFFFAOYSA-N 0.000 claims description 2
- JDQCVRQXDUGLIV-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(2-methyl-1h-indol-4-yl)urea Chemical compound C1=CC=C2NC(C)=CC2=C1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 JDQCVRQXDUGLIV-UHFFFAOYSA-N 0.000 claims description 2
- ISSPVONIBWMIFZ-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(2-methyl-1h-indol-5-yl)urea Chemical compound C=1C=C2NC(C)=CC2=CC=1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 ISSPVONIBWMIFZ-UHFFFAOYSA-N 0.000 claims description 2
- CPAIAXBFHCXXDW-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(6-fluoro-1h-indazol-4-yl)urea Chemical compound C=12C=NNC2=CC(F)=CC=1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 CPAIAXBFHCXXDW-UHFFFAOYSA-N 0.000 claims description 2
- WTFGFCWOYYKAID-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea Chemical compound C=12CC(O)CCC2=CC=CC=1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 WTFGFCWOYYKAID-UHFFFAOYSA-N 0.000 claims description 2
- NOKCIQZSXNFEOT-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(7-hydroxynaphthalen-1-yl)urea Chemical compound C12=CC(O)=CC=C2C=CC=C1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 NOKCIQZSXNFEOT-UHFFFAOYSA-N 0.000 claims description 2
- WTFGFCWOYYKAID-KRWDZBQOSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-[(7s)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea Chemical compound C([C@@H](CC1=2)O)CC1=CC=CC=2NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 WTFGFCWOYYKAID-KRWDZBQOSA-N 0.000 claims description 2
- QSVGSGPGCKGLJS-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-isoquinolin-5-ylurea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C3=CC=NC=C3C=CC=2)N1C1=CC=CC(Cl)=C1 QSVGSGPGCKGLJS-UHFFFAOYSA-N 0.000 claims description 2
- NYLBFHJDIHTBNG-UHFFFAOYSA-N 1-[[2-(3-cyano-5-fluorophenoxy)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1-methylindazol-4-yl)urea Chemical compound C1=CC=C2N(C)N=CC2=C1NC(=O)NCC1=CC(C(F)(F)F)=NN1OC1=CC(F)=CC(C#N)=C1 NYLBFHJDIHTBNG-UHFFFAOYSA-N 0.000 claims description 2
- YTLBOEQQZUNLLN-UHFFFAOYSA-N 1-[[2-(4-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(2,3-dihydro-1h-inden-5-yl)urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=C3CCCC3=CC=2)N1C1=CC=C(Cl)C=C1 YTLBOEQQZUNLLN-UHFFFAOYSA-N 0.000 claims description 2
- ACZIBYYDHGOCNU-UHFFFAOYSA-N 1-[[2-(cyclopropylmethoxy)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1h-indazol-4-yl)urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=3C=NNC=3C=CC=2)N1OCC1CC1 ACZIBYYDHGOCNU-UHFFFAOYSA-N 0.000 claims description 2
- TYQXEBDAFOEJAK-UHFFFAOYSA-N 1-[[2-(dipropylamino)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1h-indazol-4-yl)urea Chemical compound CCCN(CCC)N1N=C(C(F)(F)F)C=C1CNC(=O)NC1=CC=CC2=C1C=NN2 TYQXEBDAFOEJAK-UHFFFAOYSA-N 0.000 claims description 2
- XWSHDNGSZWCNNU-UHFFFAOYSA-N 1-[[2-(dipropylamino)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(7-hydroxynaphthalen-1-yl)urea Chemical compound CCCN(CCC)N1N=C(C(F)(F)F)C=C1CNC(=O)NC1=CC=CC2=CC=C(O)C=C12 XWSHDNGSZWCNNU-UHFFFAOYSA-N 0.000 claims description 2
- OMWDJCWGUAJWHM-UHFFFAOYSA-N 1-[[2-[(4-methoxyphenyl)methyl]-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1-methylindazol-4-yl)urea Chemical compound C1=CC(OC)=CC=C1CN1C(CNC(=O)NC=2C=3C=NN(C)C=3C=CC=2)=CC(C(F)(F)F)=N1 OMWDJCWGUAJWHM-UHFFFAOYSA-N 0.000 claims description 2
- ZBZSXUFNGWNHIG-UHFFFAOYSA-N 1-[[2-butoxy-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1-methylindazol-4-yl)urea Chemical compound CCCCON1N=C(C(F)(F)F)C=C1CNC(=O)NC1=CC=CC2=C1C=NN2C ZBZSXUFNGWNHIG-UHFFFAOYSA-N 0.000 claims description 2
- UCXMVLGBHTYHEY-UHFFFAOYSA-N 1-[[2-butoxy-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1h-indazol-4-yl)urea Chemical compound CCCCON1N=C(C(F)(F)F)C=C1CNC(=O)NC1=CC=CC2=C1C=NN2 UCXMVLGBHTYHEY-UHFFFAOYSA-N 0.000 claims description 2
- MVROELQGFGLCEL-UHFFFAOYSA-N 1-[[2-butoxy-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(2,3-dihydro-1h-inden-5-yl)urea Chemical compound CCCCON1N=C(C(F)(F)F)C=C1CNC(=O)NC1=CC=C(CCC2)C2=C1 MVROELQGFGLCEL-UHFFFAOYSA-N 0.000 claims description 2
- AOWPKXONDPZDBU-UHFFFAOYSA-N 1-[[2-cyclohexylsulfanyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1h-indazol-4-yl)urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=3C=NNC=3C=CC=2)N1SC1CCCCC1 AOWPKXONDPZDBU-UHFFFAOYSA-N 0.000 claims description 2
- WIBYBAJKSDPGEY-UHFFFAOYSA-N 1-[[2-cyclohexylsulfanyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(7-hydroxynaphthalen-1-yl)urea Chemical compound C12=CC(O)=CC=C2C=CC=C1NC(=O)NCC1=CC(C(F)(F)F)=NN1SC1CCCCC1 WIBYBAJKSDPGEY-UHFFFAOYSA-N 0.000 claims description 2
- JRSNKTPUASWXHG-UHFFFAOYSA-N 1-[[2-cyclopentyloxy-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(1h-indazol-4-yl)urea Chemical compound N1=C(C(F)(F)F)C=C(CNC(=O)NC=2C=3C=NNC=3C=CC=2)N1OC1CCCC1 JRSNKTPUASWXHG-UHFFFAOYSA-N 0.000 claims description 2
- LQRXZHRGZYEECF-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3,5-dichlorophenyl)pyrazol-3-yl]methyl]-3-(2,3-dihydro-1h-inden-5-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=C3CCCC3=CC=2)N1C1=CC(Cl)=CC(Cl)=C1 LQRXZHRGZYEECF-UHFFFAOYSA-N 0.000 claims description 2
- PSEWEOAZEQUPJX-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(2,2-difluoro-1,3-benzodioxol-5-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=C3OC(F)(F)OC3=CC=2)N1C1=CC=CC(Cl)=C1 PSEWEOAZEQUPJX-UHFFFAOYSA-N 0.000 claims description 2
- GJGZQNYMBXTWKV-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(2,3-dihydro-1,4-benzodioxin-5-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=3OCCOC=3C=CC=2)N1C1=CC=CC(Cl)=C1 GJGZQNYMBXTWKV-UHFFFAOYSA-N 0.000 claims description 2
- LXCJSADKPQQIMM-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(2,3-dihydro-1-benzofuran-7-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=3OCCC=3C=CC=2)N1C1=CC=CC(Cl)=C1 LXCJSADKPQQIMM-UHFFFAOYSA-N 0.000 claims description 2
- RBOJWINIAYOETO-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(2,3-dihydro-1h-inden-4-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=3CCCC=3C=CC=2)N1C1=CC=CC(Cl)=C1 RBOJWINIAYOETO-UHFFFAOYSA-N 0.000 claims description 2
- UEQOPMXBUSHMFR-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(2,3-dihydro-1h-inden-5-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=C3CCCC3=CC=2)N1C1=CC=CC(Cl)=C1 UEQOPMXBUSHMFR-UHFFFAOYSA-N 0.000 claims description 2
- ZVJCHXWZMKLWLG-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(4-hydroxynaphthalen-1-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C3=CC=CC=C3C(O)=CC=2)N1C1=CC=CC(Cl)=C1 ZVJCHXWZMKLWLG-UHFFFAOYSA-N 0.000 claims description 2
- HXGIGQBRICUXJO-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(5,6,7,8-tetrahydronaphthalen-1-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=3CCCCC=3C=CC=2)N1C1=CC=CC(Cl)=C1 HXGIGQBRICUXJO-UHFFFAOYSA-N 0.000 claims description 2
- JRPMAAOUUXXVTO-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(5-hydroxynaphthalen-1-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C3=CC=CC(O)=C3C=CC=2)N1C1=CC=CC(Cl)=C1 JRPMAAOUUXXVTO-UHFFFAOYSA-N 0.000 claims description 2
- FGJXRMQPCDXJDM-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(5-hydroxynaphthalen-2-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=C3C=CC=C(O)C3=CC=2)N1C1=CC=CC(Cl)=C1 FGJXRMQPCDXJDM-UHFFFAOYSA-N 0.000 claims description 2
- VAWWCRNKBKHXKJ-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(6-hydroxynaphthalen-1-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C3=CC=C(O)C=C3C=CC=2)N1C1=CC=CC(Cl)=C1 VAWWCRNKBKHXKJ-UHFFFAOYSA-N 0.000 claims description 2
- VIQDFUAVDNIDBW-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(6-hydroxynaphthalen-2-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=C3C=CC(O)=CC3=CC=2)N1C1=CC=CC(Cl)=C1 VIQDFUAVDNIDBW-UHFFFAOYSA-N 0.000 claims description 2
- IRSQKIOUTJZBJD-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(7-ethoxynaphthalen-1-yl)urea Chemical compound C12=CC(OCC)=CC=C2C=CC=C1NC(=O)NCC1=CC(C(C)(C)C)=NN1C1=CC=CC(Cl)=C1 IRSQKIOUTJZBJD-UHFFFAOYSA-N 0.000 claims description 2
- CEFMLFJJFAGHIX-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(7-hydroxynaphthalen-1-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C3=CC(O)=CC=C3C=CC=2)N1C1=CC=CC(Cl)=C1 CEFMLFJJFAGHIX-UHFFFAOYSA-N 0.000 claims description 2
- LLOWTJRQPVVLCO-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-isoquinolin-4-ylurea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C3=CC=CC=C3C=NC=2)N1C1=CC=CC(Cl)=C1 LLOWTJRQPVVLCO-UHFFFAOYSA-N 0.000 claims description 2
- HEWNNIBAZJWRKG-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-isoquinolin-5-ylurea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C3=CC=NC=C3C=CC=2)N1C1=CC=CC(Cl)=C1 HEWNNIBAZJWRKG-UHFFFAOYSA-N 0.000 claims description 2
- XQUJSMJJIJSXBT-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-isoquinolin-8-ylurea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C3=CN=CC=C3C=CC=2)N1C1=CC=CC(Cl)=C1 XQUJSMJJIJSXBT-UHFFFAOYSA-N 0.000 claims description 2
- SLAAORPLPUTGAR-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-naphthalen-1-ylurea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C3=CC=CC=C3C=CC=2)N1C1=CC=CC(Cl)=C1 SLAAORPLPUTGAR-UHFFFAOYSA-N 0.000 claims description 2
- OMUMJYZPZYEXBH-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-quinolin-3-ylurea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=C3C=CC=CC3=NC=2)N1C1=CC=CC(Cl)=C1 OMUMJYZPZYEXBH-UHFFFAOYSA-N 0.000 claims description 2
- JZCIKVQHRYDCRB-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-quinolin-5-ylurea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C3=CC=CN=C3C=CC=2)N1C1=CC=CC(Cl)=C1 JZCIKVQHRYDCRB-UHFFFAOYSA-N 0.000 claims description 2
- XMWFNGYXFLRYDZ-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-quinolin-8-ylurea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C3=NC=CC=C3C=CC=2)N1C1=CC=CC(Cl)=C1 XMWFNGYXFLRYDZ-UHFFFAOYSA-N 0.000 claims description 2
- JMRCTLVRZKFVPF-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-fluorophenyl)pyrazol-3-yl]methyl]-3-(2,3-dihydro-1h-inden-5-yl)urea Chemical compound N1=C(C(C)(C)C)C=C(CNC(=O)NC=2C=C3CCCC3=CC=2)N1C1=CC=CC(F)=C1 JMRCTLVRZKFVPF-UHFFFAOYSA-N 0.000 claims description 2
- DGNWNISPWVMJKX-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[(5-tert-butyl-2-phenylsulfanylpyrazol-3-yl)methyl]propanamide Chemical compound C=1C=C2OCOC2=CC=1C(C)C(=O)NCC1=CC(C(C)(C)C)=NN1SC1=CC=CC=C1 DGNWNISPWVMJKX-UHFFFAOYSA-N 0.000 claims description 2
- JVSALHACHKWOQW-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[[2-(3-chlorophenyl)-5-cyclopropyl-1,2,4-triazol-3-yl]methyl]propanamide Chemical compound C=1C=C2OCOC2=CC=1C(C)C(=O)NCC1=NC(C2CC2)=NN1C1=CC=CC(Cl)=C1 JVSALHACHKWOQW-UHFFFAOYSA-N 0.000 claims description 2
- NYIUIYOBGZPMOK-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[[2-(3-cyano-5-fluorophenoxy)-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide Chemical compound C=1C=C2OCOC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1OC1=CC(F)=CC(C#N)=C1 NYIUIYOBGZPMOK-UHFFFAOYSA-N 0.000 claims description 2
- ISUVDXQUJIMXAH-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[[2-[(4-fluorophenyl)methylsulfonyl-methylamino]-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide Chemical compound C=1C=C2OCOC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1N(C)S(=O)(=O)CC1=CC=C(F)C=C1 ISUVDXQUJIMXAH-UHFFFAOYSA-N 0.000 claims description 2
- QIFNVLCWVSPYAI-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[[2-cyclohexyl-5-(trifluoromethyl)-1,2,4-triazol-3-yl]methyl]propanamide Chemical compound C=1C=C2OCOC2=CC=1C(C)C(=O)NCC1=NC(C(F)(F)F)=NN1C1CCCCC1 QIFNVLCWVSPYAI-UHFFFAOYSA-N 0.000 claims description 2
- SLGNAKWPDXYJNE-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[[2-piperidin-1-yl-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide Chemical compound C=1C=C2OCOC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1N1CCCCC1 SLGNAKWPDXYJNE-UHFFFAOYSA-N 0.000 claims description 2
- BRSXXBWUFHCGGP-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[[5-tert-butyl-2-(3-chlorophenyl)-1,2,4-triazol-3-yl]methyl]propanamide Chemical compound C=1C=C2OCOC2=CC=1C(C)C(=O)NCC1=NC(C(C)(C)C)=NN1C1=CC=CC(Cl)=C1 BRSXXBWUFHCGGP-UHFFFAOYSA-N 0.000 claims description 2
- YNGPAGZWVABOFS-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[[5-tert-butyl-2-(dipropylamino)pyrazol-3-yl]methyl]propanamide Chemical compound CCCN(CCC)N1N=C(C(C)(C)C)C=C1CNC(=O)C(C)C1=CC=C(OCO2)C2=C1 YNGPAGZWVABOFS-UHFFFAOYSA-N 0.000 claims description 2
- FCMJKVVDUQLKIW-UHFFFAOYSA-N 2-(1h-indol-5-yl)-n-[[2-piperidin-1-yl-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide Chemical compound C=1C=C2NC=CC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1N1CCCCC1 FCMJKVVDUQLKIW-UHFFFAOYSA-N 0.000 claims description 2
- NFSOZGLINZBUJQ-UHFFFAOYSA-N 2-(1h-indol-5-yl)-n-[[2-pyridin-2-yloxy-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide Chemical compound C=1C=C2NC=CC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1OC1=CC=CC=N1 NFSOZGLINZBUJQ-UHFFFAOYSA-N 0.000 claims description 2
- SVHWADJUAQEVCH-UHFFFAOYSA-N 2-(2h-benzotriazol-4-yl)-n-[[2-(dipropylamino)-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide Chemical compound CCCN(CCC)N1N=C(C(F)(F)F)C=C1CNC(=O)C(C)C1=CC=CC2=C1N=NN2 SVHWADJUAQEVCH-UHFFFAOYSA-N 0.000 claims description 2
- KKLQIMDVBCCXLT-UHFFFAOYSA-N 2-(6-hydroxynaphthalen-2-yl)-n-[[2-phenylmethoxy-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide Chemical compound C=1C=C2C=C(O)C=CC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1OCC1=CC=CC=C1 KKLQIMDVBCCXLT-UHFFFAOYSA-N 0.000 claims description 2
- FTWIYSVMIFENFJ-UHFFFAOYSA-N 2-isoquinolin-5-yl-n-[[2-piperidin-1-yl-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide Chemical compound C=1C=CC2=CN=CC=C2C=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1N1CCCCC1 FTWIYSVMIFENFJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000036626 alertness Effects 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000006038 hexenyl group Chemical group 0.000 claims description 2
- 125000005980 hexynyl group Chemical group 0.000 claims description 2
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- XYBRNBFKRSDSMT-UHFFFAOYSA-N n-[(5-tert-butyl-2-piperidin-1-ylpyrazol-3-yl)methyl]-2-(2-methylquinolin-5-yl)propanamide Chemical compound C=1C=CC2=NC(C)=CC=C2C=1C(C)C(=O)NCC1=CC(C(C)(C)C)=NN1N1CCCCC1 XYBRNBFKRSDSMT-UHFFFAOYSA-N 0.000 claims description 2
- SVBJGMAESLUOCW-UHFFFAOYSA-N n-[5-[[(6-fluoro-1h-indazol-4-yl)carbamoylamino]methyl]-3-(trifluoromethyl)pyrazol-1-yl]benzamide Chemical compound C=12C=NNC2=CC(F)=CC=1NC(=O)NCC1=CC(C(F)(F)F)=NN1NC(=O)C1=CC=CC=C1 SVBJGMAESLUOCW-UHFFFAOYSA-N 0.000 claims description 2
- FMGDEUSXNFRNKQ-UHFFFAOYSA-N n-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(1-oxidoquinolin-1-ium-5-yl)propanamide Chemical compound C=1C=CC2=[N+]([O-])C=CC=C2C=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 FMGDEUSXNFRNKQ-UHFFFAOYSA-N 0.000 claims description 2
- DHFNDIAJROGNDP-UHFFFAOYSA-N n-[[2-(3-cyano-5-fluorophenoxy)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(1h-indol-5-yl)propanamide Chemical compound C=1C=C2NC=CC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1OC1=CC(F)=CC(C#N)=C1 DHFNDIAJROGNDP-UHFFFAOYSA-N 0.000 claims description 2
- IWYOVPAUQCQJKX-UHFFFAOYSA-N n-[[2-(benzenesulfonyl)-5-tert-butylpyrazol-3-yl]methyl]-2-(1,3-benzodioxol-5-yl)propanamide Chemical compound C=1C=C2OCOC2=CC=1C(C)C(=O)NCC1=CC(C(C)(C)C)=NN1S(=O)(=O)C1=CC=CC=C1 IWYOVPAUQCQJKX-UHFFFAOYSA-N 0.000 claims description 2
- OJBJQWYHVXOJDL-UHFFFAOYSA-N n-[[2-(benzenesulfonyl)-5-tert-butylpyrazol-3-yl]methyl]-2-(1h-indol-5-yl)propanamide Chemical compound C=1C=C2NC=CC2=CC=1C(C)C(=O)NCC1=CC(C(C)(C)C)=NN1S(=O)(=O)C1=CC=CC=C1 OJBJQWYHVXOJDL-UHFFFAOYSA-N 0.000 claims description 2
- MDPNLIWEIJANJB-UHFFFAOYSA-N n-[[2-(dipropylamino)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(1h-indol-5-yl)propanamide Chemical compound CCCN(CCC)N1N=C(C(F)(F)F)C=C1CNC(=O)C(C)C1=CC=C(NC=C2)C2=C1 MDPNLIWEIJANJB-UHFFFAOYSA-N 0.000 claims description 2
- KYORJAZPIUMTQB-UHFFFAOYSA-N n-[[2-(dipropylamino)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(6-hydroxynaphthalen-2-yl)propanamide Chemical compound CCCN(CCC)N1N=C(C(F)(F)F)C=C1CNC(=O)C(C)C1=CC=C(C=C(O)C=C2)C2=C1 KYORJAZPIUMTQB-UHFFFAOYSA-N 0.000 claims description 2
- LNVGZDFEMGSGDM-UHFFFAOYSA-N n-[[2-(dipropylamino)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-isoquinolin-5-ylpropanamide Chemical compound CCCN(CCC)N1N=C(C(F)(F)F)C=C1CNC(=O)C(C)C1=CC=CC2=CN=CC=C12 LNVGZDFEMGSGDM-UHFFFAOYSA-N 0.000 claims description 2
- SPZJZLDILOLYGI-UHFFFAOYSA-N n-[[2-[(4-fluorophenyl)methyl-methylamino]-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(1-methylindazol-4-yl)propanamide Chemical compound C=1C=CC=2N(C)N=CC=2C=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1N(C)CC1=CC=C(F)C=C1 SPZJZLDILOLYGI-UHFFFAOYSA-N 0.000 claims description 2
- HZKGWSPBYMGYTE-UHFFFAOYSA-N n-[[2-[(4-fluorophenyl)methyl-methylamino]-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(2-methylquinolin-5-yl)propanamide Chemical compound C=1C=CC2=NC(C)=CC=C2C=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1N(C)CC1=CC=C(F)C=C1 HZKGWSPBYMGYTE-UHFFFAOYSA-N 0.000 claims description 2
- HVZIGMALQJBFEZ-UHFFFAOYSA-N n-[[2-[(4-fluorophenyl)methyl-methylamino]-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(6-hydroxynaphthalen-2-yl)propanamide Chemical compound C=1C=C2C=C(O)C=CC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1N(C)CC1=CC=C(F)C=C1 HVZIGMALQJBFEZ-UHFFFAOYSA-N 0.000 claims description 2
- WUPBNSHDCLQUJR-UHFFFAOYSA-N n-[[2-[(4-fluorophenyl)methylsulfonyl-methylamino]-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(1-methylindazol-4-yl)propanamide Chemical compound C=1C=CC=2N(C)N=CC=2C=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1N(C)S(=O)(=O)CC1=CC=C(F)C=C1 WUPBNSHDCLQUJR-UHFFFAOYSA-N 0.000 claims description 2
- QUUGKYZWOFGLMW-UHFFFAOYSA-N n-[[2-[(4-fluorophenyl)methylsulfonyl-methylamino]-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(1h-indol-5-yl)propanamide Chemical compound C=1C=C2NC=CC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1N(C)S(=O)(=O)CC1=CC=C(F)C=C1 QUUGKYZWOFGLMW-UHFFFAOYSA-N 0.000 claims description 2
- VHOWQPNPGZVPMK-UHFFFAOYSA-N n-[[2-butoxy-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(1h-indazol-4-yl)propanamide Chemical compound CCCCON1N=C(C(F)(F)F)C=C1CNC(=O)C(C)C1=CC=CC2=C1C=NN2 VHOWQPNPGZVPMK-UHFFFAOYSA-N 0.000 claims description 2
- HCMUVGMDRKXFFL-UHFFFAOYSA-N n-[[2-butoxy-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-isoquinolin-5-ylpropanamide Chemical compound CCCCON1N=C(C(F)(F)F)C=C1CNC(=O)C(C)C1=CC=CC2=CN=CC=C12 HCMUVGMDRKXFFL-UHFFFAOYSA-N 0.000 claims description 2
- WYNWALREBZYUDI-UHFFFAOYSA-N n-[[2-cyclohexyl-5-(trifluoromethyl)-1,2,4-triazol-3-yl]methyl]-2-(2-methylquinolin-5-yl)propanamide Chemical compound C=1C=CC2=NC(C)=CC=C2C=1C(C)C(=O)NCC1=NC(C(F)(F)F)=NN1C1CCCCC1 WYNWALREBZYUDI-UHFFFAOYSA-N 0.000 claims description 2
- PEJIVHFQFYFNBQ-UHFFFAOYSA-N n-[[5-tert-butyl-2-(3,3-difluorocyclobutanecarbonyl)pyrazol-3-yl]methyl]-2-(1h-indazol-4-yl)propanamide Chemical compound C=1C=CC=2NN=CC=2C=1C(C)C(=O)NCC1=CC(C(C)(C)C)=NN1C(=O)C1CC(F)(F)C1 PEJIVHFQFYFNBQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 claims description 2
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 claims description 2
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 claims description 2
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 claims description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 claims description 2
- 125000005981 pentynyl group Chemical group 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 229910052776 Thorium Inorganic materials 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 207
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 171
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 79
- 235000019439 ethyl acetate Nutrition 0.000 description 69
- 239000011541 reaction mixture Substances 0.000 description 67
- 239000000047 product Substances 0.000 description 53
- 230000002829 reductive effect Effects 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 47
- 239000000243 solution Substances 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000004440 column chromatography Methods 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- 238000004809 thin layer chromatography Methods 0.000 description 34
- 238000012360 testing method Methods 0.000 description 33
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- 239000002904 solvent Substances 0.000 description 29
- 239000012044 organic layer Substances 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- 239000002585 base Substances 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 20
- 239000007858 starting material Substances 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- 239000011575 calcium Substances 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 17
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- 229910004298 SiO 2 Inorganic materials 0.000 description 16
- 102000003566 TRPV1 Human genes 0.000 description 16
- 101150016206 Trpv1 gene Proteins 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000003480 eluent Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 14
- 235000019341 magnesium sulphate Nutrition 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical compound CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000013067 intermediate product Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- IADPOTOXWBEFEP-UHFFFAOYSA-N 5-tert-butyl-1h-pyrazole-3-carbonitrile Chemical compound CC(C)(C)C=1C=C(C#N)NN=1 IADPOTOXWBEFEP-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
- ZHBXGHWSVIBUCQ-UHFFFAOYSA-N 5-tert-butyl-1h-pyrazol-3-amine Chemical compound CC(C)(C)C1=CC(N)=NN1 ZHBXGHWSVIBUCQ-UHFFFAOYSA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
- 230000002631 hypothermal effect Effects 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 230000004941 influx Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000003068 molecular probe Substances 0.000 description 5
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 210000003594 spinal ganglia Anatomy 0.000 description 5
- VUAXHMVRKOTJKP-UHFFFAOYSA-M 2,2-dimethylbutanoate Chemical compound CCC(C)(C)C([O-])=O VUAXHMVRKOTJKP-UHFFFAOYSA-M 0.000 description 4
- PXKSAXUKRMRORY-ZWKOTPCHSA-N 2-(3,4-dichlorophenyl)-n-[(1s,2r)-2-(2,5-dihydropyrrol-1-yl)cyclohexyl]-n-methylacetamide Chemical compound N1([C@@H]2CCCC[C@@H]2N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CC=CC1 PXKSAXUKRMRORY-ZWKOTPCHSA-N 0.000 description 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 4
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101150065749 Churc1 gene Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102100038239 Protein Churchill Human genes 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 230000001598 anti-natriuretic effect Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- PTTURPGPYPKOPH-UHFFFAOYSA-N methyl 4-(phenoxycarbonylamino)indazole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC)N=CC2=C1NC(=O)OC1=CC=CC=C1 PTTURPGPYPKOPH-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010020843 Hyperthermia Diseases 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- OPZKBPQVWDSATI-KHPPLWFESA-N N-Vanillyloleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-KHPPLWFESA-N 0.000 description 3
- 238000011785 NMRI mouse Methods 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 239000012954 diazonium Substances 0.000 description 3
- 150000001989 diazonium salts Chemical class 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000036031 hyperthermia Effects 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- OPZKBPQVWDSATI-UHFFFAOYSA-N oleoyl vanillylamide Natural products CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-UHFFFAOYSA-N 0.000 description 3
- 229950010717 olvanil Drugs 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- GFPJLZASIVURDY-UHFFFAOYSA-N (3-chlorophenyl)hydrazine Chemical compound NNC1=CC=CC(Cl)=C1 GFPJLZASIVURDY-UHFFFAOYSA-N 0.000 description 2
- RBUPNPJAMUJKAN-UHFFFAOYSA-N (5-tert-butyl-2-methylpyrazol-3-yl)methanamine Chemical compound CN1N=C(C(C)(C)C)C=C1CN RBUPNPJAMUJKAN-UHFFFAOYSA-N 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- FFFIRKXTFQCCKJ-UHFFFAOYSA-N 2,4,6-trimethylbenzoic acid Chemical compound CC1=CC(C)=C(C(O)=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-N 0.000 description 2
- ODVLMCWNGKLROU-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OCOC2=C1 ODVLMCWNGKLROU-UHFFFAOYSA-N 0.000 description 2
- QIUFWAUQCRKTJD-UHFFFAOYSA-N 2-(1-methylsulfonyl-2,3-dihydroindol-5-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C2N(S(C)(=O)=O)CCC2=C1 QIUFWAUQCRKTJD-UHFFFAOYSA-N 0.000 description 2
- BVRNERFWPQRVJB-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-yl)acetic acid Chemical compound O1CCOC2=CC(CC(=O)O)=CC=C21 BVRNERFWPQRVJB-UHFFFAOYSA-N 0.000 description 2
- UIBJPVZRTBSXSA-UHFFFAOYSA-N 2-(7-hydroxynaphthalen-1-yl)propanoic acid Chemical compound C1=C(O)C=C2C(C(C(O)=O)C)=CC=CC2=C1 UIBJPVZRTBSXSA-UHFFFAOYSA-N 0.000 description 2
- VIKBNMWOLLIQPG-UHFFFAOYSA-N 2-methyldecanedioic acid Chemical compound OC(=O)C(C)CCCCCCCC(O)=O VIKBNMWOLLIQPG-UHFFFAOYSA-N 0.000 description 2
- GUGQQGROXHPINL-UHFFFAOYSA-N 2-oxobutanoyl chloride Chemical compound CCC(=O)C(Cl)=O GUGQQGROXHPINL-UHFFFAOYSA-N 0.000 description 2
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- OAAGDVLVOKMRCQ-UHFFFAOYSA-N 5-piperidin-4-yl-3-pyridin-4-yl-1,2,4-oxadiazole Chemical compound C1CNCCC1C1=NC(C=2C=CN=CC=2)=NO1 OAAGDVLVOKMRCQ-UHFFFAOYSA-N 0.000 description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 239000007756 Ham's F12 Nutrient Mixture Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- KPKDNZMHJYDLFH-UHFFFAOYSA-N [2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methanamine Chemical compound NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 KPKDNZMHJYDLFH-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000003502 anti-nociceptive effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- CYKXDHXBWOTQKY-UHFFFAOYSA-L dibromonickel;2-pyridin-2-ylpyridine Chemical compound Br[Ni]Br.N1=CC=CC=C1C1=CC=CC=N1 CYKXDHXBWOTQKY-UHFFFAOYSA-L 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- FYAQQULBLMNGAH-UHFFFAOYSA-N hexane-1-sulfonic acid Chemical compound CCCCCCS(O)(=O)=O FYAQQULBLMNGAH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000012948 isocyanate Chemical class 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- PJKYZAZBIUPASP-UHFFFAOYSA-N methyl 2-(1-hydroxy-2,3-dihydro-1h-inden-4-yl)propanoate Chemical compound COC(=O)C(C)C1=CC=CC2=C1CCC2O PJKYZAZBIUPASP-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- VJLYHMVBXPGYLB-UHFFFAOYSA-N 1-(1-methylisoquinolin-5-yl)-3-[[2-piperidin-1-yl-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea Chemical compound C1=CC=C2C(C)=NC=CC2=C1NC(=O)NCC1=CC(C(F)(F)F)=NN1N1CCCCC1 VJLYHMVBXPGYLB-UHFFFAOYSA-N 0.000 description 1
- WTFGFCWOYYKAID-QGZVFWFLSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-[(7r)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea Chemical compound C([C@H](CC1=2)O)CC1=CC=CC=2NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 WTFGFCWOYYKAID-QGZVFWFLSA-N 0.000 description 1
- AWXGTGQTIIDGET-UHFFFAOYSA-N 1-[[2-(6-chloropyridin-2-yl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(7-hydroxynaphthalen-1-yl)urea Chemical compound C12=CC(O)=CC=C2C=CC=C1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=N1 AWXGTGQTIIDGET-UHFFFAOYSA-N 0.000 description 1
- LUBCKCSIZNBBRJ-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(6-chloropyridin-2-yl)pyrazol-3-yl]methyl]-3-(1-methylisoquinolin-5-yl)urea Chemical compound C1=CC=C2C(C)=NC=CC2=C1NC(=O)NCC1=CC(C(C)(C)C)=NN1C1=CC=CC(Cl)=N1 LUBCKCSIZNBBRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- PAUQGTCIXXKNBE-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[[5-tert-butyl-2-(6-chloropyridin-2-yl)pyrazol-3-yl]methyl]propanamide Chemical compound C=1C=C2OCOC2=CC=1C(C)C(=O)NCC1=CC(C(C)(C)C)=NN1C1=CC=CC(Cl)=N1 PAUQGTCIXXKNBE-UHFFFAOYSA-N 0.000 description 1
- VUNWUTPFVAAMOC-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C2OCOC2=C1 VUNWUTPFVAAMOC-UHFFFAOYSA-N 0.000 description 1
- HRYFKWATXKFOBY-UHFFFAOYSA-N 2-(1,3-benzoxazol-5-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C2OC=NC2=C1 HRYFKWATXKFOBY-UHFFFAOYSA-N 0.000 description 1
- IRDBTINULKINKY-UHFFFAOYSA-N 2-(1,3-benzoxazol-6-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C2N=COC2=C1 IRDBTINULKINKY-UHFFFAOYSA-N 0.000 description 1
- TUOXIGDZYAIILL-UHFFFAOYSA-N 2-(1-hydroxy-2,3-dihydro-1h-inden-4-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC2=C1CCC2O TUOXIGDZYAIILL-UHFFFAOYSA-N 0.000 description 1
- NVCNSYVQRROGTL-UHFFFAOYSA-N 2-(1-oxo-2,3-dihydroinden-4-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC2=C1CCC2=O NVCNSYVQRROGTL-UHFFFAOYSA-N 0.000 description 1
- WIUXWRYRVNLBPM-UHFFFAOYSA-N 2-(1h-indazol-5-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C2NN=CC2=C1 WIUXWRYRVNLBPM-UHFFFAOYSA-N 0.000 description 1
- VSBHPXBSNIIKKL-UHFFFAOYSA-N 2-(1h-indol-5-yl)-n-[[2-pyridin-4-yloxy-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide Chemical compound C=1C=C2NC=CC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1OC1=CC=NC=C1 VSBHPXBSNIIKKL-UHFFFAOYSA-N 0.000 description 1
- DWXSYDKEWORWBT-UHFFFAOYSA-N 2-(2-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1Br DWXSYDKEWORWBT-UHFFFAOYSA-N 0.000 description 1
- GNOJQFGBAWNDCI-UHFFFAOYSA-N 2-(2-hydroxy-2,3-dihydro-1h-inden-4-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC2=C1CC(O)C2 GNOJQFGBAWNDCI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- SWTYEGKNPYREDM-UHFFFAOYSA-N 2-(2-methylquinolin-5-yl)-n-[[2-piperidin-1-yl-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide Chemical compound C=1C=CC2=NC(C)=CC=C2C=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1N1CCCCC1 SWTYEGKNPYREDM-UHFFFAOYSA-N 0.000 description 1
- UTAFKCYCPQYPDS-UHFFFAOYSA-N 2-(3h-inden-4-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC2=C1CC=C2 UTAFKCYCPQYPDS-UHFFFAOYSA-N 0.000 description 1
- OVRVKIZTOGLMAH-UHFFFAOYSA-N 2-(5,6,7,8-tetrahydronaphthalen-1-yl)propanoic acid Chemical compound C1CCCC2=C1C=CC=C2C(C(O)=O)C OVRVKIZTOGLMAH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GMRKWWIDEVJMSP-UHFFFAOYSA-N 2-[amino-(4-chlorophenyl)methyl]-3-[(2-methylpropan-2-yl)oxy]-3-oxopropanoic acid Chemical compound CC(C)(C)OC(=O)C(C(O)=O)C(N)C1=CC=C(Cl)C=C1 GMRKWWIDEVJMSP-UHFFFAOYSA-N 0.000 description 1
- VKSJVMZEQNIBNA-UHFFFAOYSA-N 2-chloroethyl propanoate Chemical compound CCC(=O)OCCCl VKSJVMZEQNIBNA-UHFFFAOYSA-N 0.000 description 1
- OYUNTGBISCIYPW-UHFFFAOYSA-N 2-chloroprop-2-enenitrile Chemical compound ClC(=C)C#N OYUNTGBISCIYPW-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VMUXSMXIQBNMGZ-UHFFFAOYSA-N 3,4-dihydrocoumarin Chemical compound C1=CC=C2OC(=O)CCC2=C1 VMUXSMXIQBNMGZ-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MXZMACXOMZKYHJ-UHFFFAOYSA-N 4,4-dimethyl-3-oxopentanenitrile Chemical compound CC(C)(C)C(=O)CC#N MXZMACXOMZKYHJ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- SCWNNOCLLOHZIG-UHFFFAOYSA-N 5,6,7,8-tetrahydro-1-naphthol Chemical compound C1CCCC2=C1C=CC=C2O SCWNNOCLLOHZIG-UHFFFAOYSA-N 0.000 description 1
- KLTSAXZCGBYCPU-UHFFFAOYSA-N 5-bromo-1-methylsulfonyl-2,3-dihydroindole Chemical compound BrC1=CC=C2N(S(=O)(=O)C)CCC2=C1 KLTSAXZCGBYCPU-UHFFFAOYSA-N 0.000 description 1
- QEDCHCLHHGGYBT-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1h-indole Chemical compound BrC1=CC=C2NCCC2=C1 QEDCHCLHHGGYBT-UHFFFAOYSA-N 0.000 description 1
- RJUFYSUNQJMDLZ-UHFFFAOYSA-N 8-bromonaphthalen-1-ol Chemical compound C1=CC(Br)=C2C(O)=CC=CC2=C1 RJUFYSUNQJMDLZ-UHFFFAOYSA-N 0.000 description 1
- 241000251169 Alopias vulpinus Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 206010006487 Bronchostenosis Diseases 0.000 description 1
- UTUOEFZRQODMBJ-UHFFFAOYSA-N C1(CCCC2=CC=CC=C12)C1=NC(=NC=C1)C1=NOC=C1 Chemical class C1(CCCC2=CC=CC=C12)C1=NC(=NC=C1)C1=NOC=C1 UTUOEFZRQODMBJ-UHFFFAOYSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010028741 Nasal inflammation Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 229910021585 Nickel(II) bromide Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003574 anti-allodynic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 description 1
- DMSHWWDRAYHEBS-UHFFFAOYSA-N dihydrocoumarin Natural products C1CC(=O)OC2=C1C=C(OC)C(OC)=C2 DMSHWWDRAYHEBS-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- FWUQPSOUPSUZAF-UHFFFAOYSA-N methyl 2-(1,3-benzoxazol-5-yl)acetate Chemical compound COC(=O)CC1=CC=C2OC=NC2=C1 FWUQPSOUPSUZAF-UHFFFAOYSA-N 0.000 description 1
- HDWLMCNRVZWWNB-UHFFFAOYSA-N methyl 2-(1,3-benzoxazol-5-yl)propanoate Chemical compound COC(=O)C(C)C1=CC=C2OC=NC2=C1 HDWLMCNRVZWWNB-UHFFFAOYSA-N 0.000 description 1
- SPCRIUSIYZYZKN-UHFFFAOYSA-N methyl 2-(4-hydroxy-3-nitrophenyl)acetate Chemical compound COC(=O)CC1=CC=C(O)C([N+]([O-])=O)=C1 SPCRIUSIYZYZKN-UHFFFAOYSA-N 0.000 description 1
- XGDZEDRBLVIUMX-UHFFFAOYSA-N methyl 2-(4-hydroxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(O)C=C1 XGDZEDRBLVIUMX-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- BNRABWNMDXMOCS-UHFFFAOYSA-N n-[[2-(3-chlorophenyl)-5-(trifluoromethyl)-1,2,4-triazol-3-yl]methyl]-2-(6-hydroxynaphthalen-2-yl)propanamide Chemical compound C=1C=C2C=C(O)C=CC2=CC=1C(C)C(=O)NCC1=NC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 BNRABWNMDXMOCS-UHFFFAOYSA-N 0.000 description 1
- RJWPXUOBFOTEFU-UHFFFAOYSA-N n-[[2-(6-chloropyridin-2-yl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(1h-indol-5-yl)propanamide Chemical compound C=1C=C2NC=CC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=N1 RJWPXUOBFOTEFU-UHFFFAOYSA-N 0.000 description 1
- LWXJPNJUCYFNLR-UHFFFAOYSA-N n-[[2-(6-chloropyridin-2-yl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(6-hydroxynaphthalen-2-yl)propanamide Chemical compound C=1C=C2C=C(O)C=CC2=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=N1 LWXJPNJUCYFNLR-UHFFFAOYSA-N 0.000 description 1
- HUZMJAHISADZIE-UHFFFAOYSA-N n-[[5-tert-butyl-2-(6-chloropyridin-2-yl)pyrazol-3-yl]methyl]-2-isoquinolin-5-ylpropanamide Chemical compound C=1C=CC2=CN=CC=C2C=1C(C)C(=O)NCC1=CC(C(C)(C)C)=NN1C1=CC=CC(Cl)=N1 HUZMJAHISADZIE-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical group [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QAZLUNIWYYOJPC-UHFFFAOYSA-M sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- FWMUJAIKEJWSSY-UHFFFAOYSA-N sulfur dichloride Chemical compound ClSCl FWMUJAIKEJWSSY-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17627709P | 2009-05-07 | 2009-05-07 | |
| EP09006221 | 2009-05-07 | ||
| EP09006221.7 | 2009-05-07 | ||
| US61/176,277 | 2009-05-07 | ||
| PCT/EP2010/002785 WO2010127855A1 (en) | 2009-05-07 | 2010-05-06 | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526061A JP2012526061A (ja) | 2012-10-25 |
| JP2012526061A5 JP2012526061A5 (enExample) | 2015-01-22 |
| JP5767631B2 true JP5767631B2 (ja) | 2015-08-19 |
Family
ID=40848721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508950A Expired - Fee Related JP5767631B2 (ja) | 2009-05-07 | 2010-05-06 | バニロイド受容体リガンドとしての置換された芳香族カルボキサミドおよび尿素誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8334315B2 (enExample) |
| EP (1) | EP2427436B1 (enExample) |
| JP (1) | JP5767631B2 (enExample) |
| AR (1) | AR076753A1 (enExample) |
| AU (1) | AU2010244684B2 (enExample) |
| BR (1) | BRPI1011192A2 (enExample) |
| CA (1) | CA2758289A1 (enExample) |
| DK (1) | DK2427436T3 (enExample) |
| ES (1) | ES2402805T3 (enExample) |
| HR (1) | HRP20130128T1 (enExample) |
| MX (1) | MX2011011800A (enExample) |
| PL (1) | PL2427436T3 (enExample) |
| PT (1) | PT2427436E (enExample) |
| SI (1) | SI2427436T1 (enExample) |
| TW (1) | TWI504589B (enExample) |
| WO (1) | WO2010127855A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009067493A2 (en) * | 2007-11-19 | 2009-05-28 | Envivo Pharmaceuticals, Inc. | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
| JP2011507909A (ja) | 2007-12-20 | 2011-03-10 | エンビボ ファーマシューティカルズ インコーポレイテッド | 四置換ベンゼン |
| US8946204B2 (en) * | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| RU2553392C2 (ru) * | 2009-05-07 | 2015-06-10 | Грюненталь Гмбх | Замещенные фенилмочевины и фениламиды в качестве лигандов ваниллоидных рецепторов |
| RU2017144535A (ru) | 2010-03-30 | 2019-02-18 | Версеон Корпорейшн | Мультизамещенные ароматические соединения в качестве ингибиторов тромбина |
| BR112014001714A2 (pt) | 2011-07-26 | 2017-02-14 | Gruenenthal Gmbh | derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide |
| KR20140049026A (ko) * | 2011-07-26 | 2014-04-24 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체 리간드로서의 치환된 헤테로방향족 피라졸―함유 카복스아미드 및 우레아 유도체 |
| EP2763673B1 (en) * | 2011-09-15 | 2018-08-01 | Taipei Medical University | Use of indolyl hydroxamates for treating heart failure or neuronal injury |
| KR20140093260A (ko) | 2011-11-09 | 2014-07-25 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체 리간드로서의 ｎ－사이클릭 그룹으로 치환된 페닐 모이어티를 갖는 치환된 피라졸릴계 카복스아미드 및 우레아 유도체들 |
| KR20140096351A (ko) | 2011-11-09 | 2014-08-05 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체 리간드로서의 ｎ함유 그룹으로 치환된 페닐 모이어티를 갖는 치환된 피라졸릴계 카복스아미드 및 우레아 유도체들 |
| WO2013068467A1 (en) | 2011-11-09 | 2013-05-16 | Grünenthal GmbH | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a co-containing group as vanilloid receptor ligands |
| MX2014005233A (es) | 2011-11-09 | 2014-08-22 | Grünenthal GmbH | Derivados de carboxamida y urea a base de pirazolilos sutituidos que contienen una porcion fenilo sustituida con un grupo que contiene so2 como ligandos del receptor de vanilloide. |
| CN103889961A (zh) | 2011-11-09 | 2014-06-25 | 格吕伦塔尔有限公司 | 作为辣椒素类似物受体配体的携带被含氧基团取代的苯基的被取代的基于吡唑基的甲酰胺及脲衍生物 |
| PL2968297T3 (pl) | 2013-03-15 | 2019-04-30 | Verseon Corp | Wielopodstawione związki aromatyczne jako inhibitory protezy serynowej |
| BR112015023214A8 (pt) | 2013-03-15 | 2019-12-24 | Verseon Corp | composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica |
| CN103787895A (zh) * | 2014-01-23 | 2014-05-14 | 安徽华润涂料有限公司 | 一种4-溴-2-甲基苯胺合成的生产工艺 |
| EP3194369A4 (en) | 2014-09-17 | 2018-02-28 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| WO2016114312A1 (ja) | 2015-01-13 | 2016-07-21 | 日産化学工業株式会社 | 反応混合物中のスズ化合物の処理方法 |
| CA2977993A1 (en) | 2015-02-27 | 2016-09-01 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| PT3319959T (pt) | 2015-07-06 | 2021-12-06 | Alkermes Inc | Inibidores hetero-halo de histona desacetilase |
| WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| EP3130590A1 (en) * | 2015-08-13 | 2017-02-15 | Grünenthal GmbH | Aromatic aza compounds as vr1/trpv1 ligands |
| AU2017217536A1 (en) | 2016-02-09 | 2018-08-09 | Inventisbio Inc. | Inhibitor of indoleamine-2,3-dioxygenase (IDO) |
| EP3241830A1 (de) | 2016-05-04 | 2017-11-08 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| CN107805221A (zh) * | 2016-09-09 | 2018-03-16 | 西华大学 | 一种制备1h‑吲唑衍生物的方法 |
| WO2018093569A1 (en) | 2016-11-03 | 2018-05-24 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors |
| MX394242B (es) | 2017-01-11 | 2025-03-24 | Rodin Therapeutics Inc | Inhibidores biciclicos de histona desacetilasa |
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| MX2020001484A (es) | 2017-08-07 | 2020-08-20 | Rodin Therapeutics Inc | Inhibidores bicíclicos de la histona desacetilasa. |
| CN110627683A (zh) * | 2018-06-25 | 2019-12-31 | 广东东阳光药业有限公司 | 一种茚满酮中间体的制备方法 |
| HUE068289T2 (hu) * | 2019-08-23 | 2024-12-28 | Mochida Pharm Co Ltd | Eljárás heterociklidén-acetamid származékok elõállítására |
| WO2021039023A1 (ja) | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
| CN112409191A (zh) * | 2019-08-23 | 2021-02-26 | 持田制药株式会社 | 光学活性的氨基醇的制备方法 |
| MX2022002017A (es) | 2019-08-23 | 2022-03-11 | Mochida Pharm Co Ltd | Metodo para producir derivado de heterociclideno acetamida. |
| CN110563693B (zh) * | 2019-09-30 | 2022-10-21 | 苏州弘森药业股份有限公司 | 一种胡椒环制备方法 |
| EP4555128A1 (de) | 2022-07-11 | 2025-05-21 | Bayer Aktiengesellschaft | Elektrochemische synthese von pyrazolinen und pyrazolen |
| CN115282134B (zh) * | 2022-07-20 | 2023-06-23 | 天津中医药大学 | 辣椒素在制备治疗脆性x染色体综合征的药物中的应用 |
| CN121039092A (zh) * | 2023-04-25 | 2025-11-28 | Jw制药公司 | 制备4-氨基茚满的方法和制备二氢茚基-吡唑并[3,4-b]吡啶胺化合物的方法 |
| CN117304009A (zh) * | 2023-10-10 | 2023-12-29 | 韶远科技（上海)有限公司 | 一种3-氟-4-甲基-8-氧代-5,6,7,8-四氢萘的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR230994A1 (es) * | 1981-08-31 | 1984-08-31 | Pfizer | Procedimiento para preparar compuesto de 3'-substituido-5'-(2-amino-4-piridil)-1',2',4'-triazol |
| JPH06157469A (ja) * | 1992-11-13 | 1994-06-03 | Ube Ind Ltd | ピラゾールカルボニルウレア誘導体、その製法及び有害生物防除剤 |
| US6455559B1 (en) * | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| JP4471842B2 (ja) | 2002-03-27 | 2010-06-02 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | アミド化合物および該化合物を用いる方法 |
| US7393873B2 (en) | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
| US7750160B2 (en) | 2003-11-13 | 2010-07-06 | Ambit Biosciences Corporation | Isoxazolyl urea derivatives as kinase modulators |
| JP2007535565A (ja) | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | 癌の治療に有用な置換ピラゾリル尿素誘導体 |
| DE102005037499A1 (de) * | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
| JP2009518298A (ja) | 2005-12-01 | 2009-05-07 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療に有用な尿素化合物 |
| WO2008011557A2 (en) * | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
| WO2008059370A2 (en) * | 2006-11-17 | 2008-05-22 | Pfizer Japan Inc. | Substituted bicyclocarboxyamide compounds |
| TW200833663A (en) | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
| WO2008137102A2 (en) * | 2007-05-04 | 2008-11-13 | Torreypines Therapeutics, Inc. | Methods of modulating amyloid beta and compounds useful therefor |
| JP2010083763A (ja) * | 2008-09-29 | 2010-04-15 | Mitsui Chemicals Inc | ピラゾール誘導体およびその製造方法、ならびに殺菌剤 |
-
2010
- 2010-05-06 AR ARP100101548A patent/AR076753A1/es unknown
- 2010-05-06 DK DK10720996.7T patent/DK2427436T3/da active
- 2010-05-06 SI SI201030151T patent/SI2427436T1/sl unknown
- 2010-05-06 PL PL10720996T patent/PL2427436T3/pl unknown
- 2010-05-06 ES ES10720996T patent/ES2402805T3/es active Active
- 2010-05-06 US US12/775,155 patent/US8334315B2/en not_active Expired - Fee Related
- 2010-05-06 HR HRP20130128AT patent/HRP20130128T1/hr unknown
- 2010-05-06 JP JP2012508950A patent/JP5767631B2/ja not_active Expired - Fee Related
- 2010-05-06 WO PCT/EP2010/002785 patent/WO2010127855A1/en not_active Ceased
- 2010-05-06 PT PT107209967T patent/PT2427436E/pt unknown
- 2010-05-06 BR BRPI1011192A patent/BRPI1011192A2/pt not_active IP Right Cessation
- 2010-05-06 EP EP10720996A patent/EP2427436B1/en not_active Not-in-force
- 2010-05-06 AU AU2010244684A patent/AU2010244684B2/en not_active Ceased
- 2010-05-06 MX MX2011011800A patent/MX2011011800A/es active IP Right Grant
- 2010-05-06 TW TW099114463A patent/TWI504589B/zh not_active IP Right Cessation
- 2010-05-06 CA CA2758289A patent/CA2758289A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010244684A1 (en) | 2011-11-03 |
| AR076753A1 (es) | 2011-07-06 |
| WO2010127855A1 (en) | 2010-11-11 |
| PT2427436E (pt) | 2013-03-04 |
| TWI504589B (zh) | 2015-10-21 |
| PL2427436T3 (pl) | 2013-06-28 |
| US8334315B2 (en) | 2012-12-18 |
| SI2427436T1 (sl) | 2013-04-30 |
| TW201120010A (en) | 2011-06-16 |
| BRPI1011192A2 (pt) | 2016-03-15 |
| EP2427436B1 (en) | 2013-01-09 |
| HRP20130128T1 (hr) | 2013-03-31 |
| DK2427436T3 (da) | 2013-04-02 |
| CA2758289A1 (en) | 2010-11-11 |
| ES2402805T3 (es) | 2013-05-09 |
| US20110003795A1 (en) | 2011-01-06 |
| EP2427436A1 (en) | 2012-03-14 |
| MX2011011800A (es) | 2012-01-27 |
| AU2010244684B2 (en) | 2014-07-03 |
| JP2012526061A (ja) | 2012-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5767631B2 (ja) | バニロイド受容体リガンドとしての置換された芳香族カルボキサミドおよび尿素誘導体 | |
| JP5745505B2 (ja) | バニロイド受容体リガンドとしての置換フェニル尿素および置換フェニルアミド | |
| JP2013545740A (ja) | バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体 | |
| US9624215B2 (en) | Amine derivative or salt thereof | |
| JP2013534229A (ja) | バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体 | |
| JP5587246B2 (ja) | レニン阻害剤としての３，４−置換ピペリジン誘導体 | |
| CN103613527B (zh) | 可用作单胺再摄取抑制剂的n,n-取代的3-氨基吡咯烷化合物 | |
| US20110301156A1 (en) | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | |
| EA008801B1 (ru) | Получение арилалкилкарбаматных производных и их применение в терапии | |
| JP2014532746A (ja) | バニロイド受容体リガンドとしての、ｃｏ含有基で置換されたフェニル部分を担持する置換ピラゾリルをベースとするカルボキサミドおよび尿素誘導体 | |
| CN110105286B (zh) | 一种含有脲素骨架的取代杂环类化合物及其制备方法和用途 | |
| KR101070176B1 (ko) | Ｃｂ１에 길항 활성을 갖는 1ｈ-파이라졸-3-아마이드계 화합물 또는 1ｈ-파이라졸-3-옥소아세트아마이드계 화학물 유도체 및 이를 포함하는 약제학적 조성물 | |
| JP2013542231A (ja) | バニロイド受容体リガンドとしての置換された二環式芳香族カルボキサミド誘導体および尿素誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130411 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140627 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140709 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141002 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141009 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141104 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141111 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20141201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141202 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150603 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150619 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5767631 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |